Topic: venture capital (VC)
5AM Ventures has closed two new biotech-focused capital funds, totaling $497 million in commitments.
David Schenkein will co-lead the life science team at the fund, formerly known as Google Ventures, with Krishna Yeshwant.
Nuvaira has raised $79 million in equity financing to continue late-stage clinical development of its device-based treatment for COPD in the U.S.
The series A, which was backed by Andera Partners and Canaan, will fund work to render more tumors vulnerable to checkpoint inhibitors.
The fund will pump the money into biotechs and other longevity startups based around the world in seed to series B rounds.
Dewpoint Therapeutics will develop a drug platform targeting biomolecular condensates, an “understudied” type of organelle found inside cells.
Lyndra Therapeutics has raised $55 million to carry out a phase 2 trial of a long-acting pill for the treatment of schizophrenia.
BridgeBio Pharma has bagged a whopping $299.2 million to advance its genetic disease pipeline, which includes more than a dozen assets.
Attune Pharmaceuticals raised $23 million in series B financing to push its oral drug for hereditary angioedema through phase 2.
Wren Therapeutics will use the series A round to advance its research into drugs to treat protein-misfolding diseases such as Alzheimer’s.